Eastern Cooperative Oncology Group (ECOG) Performance Status
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- ECOG 00–0
- ECOG 11–1
- ECOG 22–2
- ECOG 33–3
The Eastern Cooperative Oncology Group (ECOG) Performance Status calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include performance status. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Determines patient's ability to tolerate therapies in severe illness, specifically for chemotherapy. Simple 5-point scale that describes patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability.
Clinical Indication
The Eastern Cooperative Oncology Group (ECOG) Performance Status is indicated for bedside clinical practice to support Determines patient's ability to tolerate therapies in severe illness, specifically for chemotherapy. Simple 5-point scale that describes patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Widely used for determining eligibility for clinical trials and treatment decisions..
Direct assessment scale with 5 defined levels (0-4) based on patient's functional status and ability to perform activities of daily living. No mathematical calculation required - clinician selects appropriate level based on patient assessment.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| performance_status | string | Yes | Patient's current performance status based on functional assessment |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | ECOG 0 | Fully active |
| 1–1 | ECOG 1 | Restricted in strenuous activity |
| 2–2 | ECOG 2 | Ambulatory but unable to work |
| 3–3 | ECOG 3 | Limited self-care |
| 4–4 | ECOG 4 | Completely disabled |
Evidence-Based References (EBM)
- Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-55. doi: 10.1097/00000421-198212000-00014.DOI: 10.1097/00000421-198212000-00014
- Zubrod CG, Schneiderman M, Frei E, Brindley C, Gold GL, Shnider B, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis. 1960;11:7-33. doi: 10.1016/0021-9681(60)90137-5.DOI: 10.1016/0021-9681(60)90137-5
- Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 1996;32A(7):1135-41. doi: 10.1016/0959-8049(95)00664-8.DOI: 10.1016/0959-8049(95)00664-8
- Ma C, Bandukwala S, Burman D, Bryson J, Seccareccia D, Banerjee S, et al. Interconversion of three measures of performance status: an empirical analysis. Eur J Cancer. 2010;46(18):3175-83. doi: 10.1016/j.ejca.2010.06.126.DOI: 10.1016/j.ejca.2010.06.126